Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01858012 · ClinicalTrials.gov registry record

Insulin Resistance in HCV Infection

A clinical trial of Insulin Resistance, sponsored by University of California, San Francisco.

Active
Registry status
250
Enrollment target
1
Study location

NCT01858012 is a study of Insulin Resistance that is active but no longer recruiting, run by University of California, San Francisco. The registered enrollment target is 250 participants, roughly in line with the 243-participant average among 120 other Insulin Resistance trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01858012, a study of Insulin Resistance, is active but no longer recruiting, sponsored by University of California, San Francisco.

ACTIVE NOT RECRUITING
Registry status
250 participants
Enrollment target
1
Study location

Study Summary

The study hypothesis is that the means by which HCV induces glucose intolerance is through impairment of B-cell function and compensatory hyperinsulinemia in predisposed Latinos with insulin resistance and that HCV eradication improves these abnormalities. It is also hypothesized that moderate alcohol consumption impact insulin sensitivity and secretion with Latinos with or without HCV infection.

Conditions Studied

Interventions

  • BEHAVIORAL Moderate alcohol cessation

Study Locations (1)

California

  • University of california San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 250 participants
Start Date 2008-01-01
Est. Completion 2026-12-31

What the Registry Record Tells You About NCT01858012

The ClinicalTrials.gov registry entry for NCT01858012 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 250 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 243-participant average among 120 other Insulin Resistance trials with a reported enrollment target. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Moderate alcohol cessation is the first listed.

NCT01858012 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT01858012 about?

NCT01858012 is a clinical study titled "Insulin Resistance in HCV Infection". The study hypothesis is that the means by which HCV induces glucose intolerance is through impairment of B-cell function and compensatory hyperinsulinemia in predisposed Latinos with insulin resistance and that HCV eradication improves these abnormalities. It is also hypothesized that moderate alcoh...

What is the current status of trial NCT01858012?

This trial is currently active not recruiting. The enrollment target is 250 participants. The study started on 2008-01-01. Estimated completion is 2026-12-31.

What conditions does trial NCT01858012 study?

This clinical trial studies the following conditions: Insulin Resistance.

What interventions are being tested in trial NCT01858012?

The interventions under investigation include: Moderate alcohol cessation (BEHAVIORAL).

Who is sponsoring clinical trial NCT01858012?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01858012 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Insulin Resistance

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.